Abeta2m Amyloidosis C5680053
Amyloidosis from abnormal beta-2-microglobulin protein, often in dialysis patients. Seen with long-term kidney treatment. Causes joint and bone pain.
Key facts at a glance
- ICD-10
- R69
- ICD-11
- MA00.0
- Body system
- metabolic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Carpal Tunnel Syndrome
Numbness, tingling, and weakness in the hands and fingers due to compression of the median nerve from amyloid deposits.
Seek immediate care if you experience persistent numbness, weakness, or burning pain in your hands, as delayed treatment can cause permanent nerve damage.
Pathological Bone Fractures
Spontaneous bone fractures, particularly in the spine, hips, and long bones, caused by amyloid-filled bone cysts weakening bone structure.
Seek emergency care immediately if you experience sudden severe bone pain, especially in the back, hip, or after minimal trauma, as this may indicate a fracture.
Joint Pain and Stiffness
(musculoskeletal)Persistent pain and morning stiffness in multiple joints, particularly affecting the shoulders, wrists, hips, and knees.
Frequency: 80-90% of patients
Shoulder Pain and Stiffness
(musculoskeletal)Pain and limited range of motion in the shoulders, often involving the rotator cuff and surrounding tissues.
Frequency: 70-85% of patients
Tendon Rupture
(musculoskeletal)Spontaneous rupture of tendons, most commonly affecting the quadriceps tendon and Achilles tendon, due to amyloid infiltration.
Frequency: 5-15% of patients
Cervical Spondyloarthropathy
(musculoskeletal)Degeneration and instability of the cervical spine with amyloid deposits causing neck pain, stiffness, and potential spinal cord compression.
Frequency: 30-50% of patients
Subcutaneous Nodules
(dermatologic)Firm, non-tender nodules under the skin, typically appearing on the fingers, hands, wrists, and forearms.
Frequency: 20-40% of patients
Chronic Fatigue
(constitutional)Persistent tiredness and lack of energy that does not improve with rest, common in patients with advanced dialysis-related amyloidosis.
Frequency: 40-60% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Kidney transplantation
Kidney transplantation is the definitive treatment for dialysis-related amyloidosis as it removes the source of beta-2-microglobulin accumulation and restores normal clearance. Successful transplantation can lead to regression of existing amyloid deposits.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
High-flux hemodialysis
High-flux dialysis membranes and hemodiafiltration enhance beta-2-microglobulin clearance compared to standard dialysis. Extended hemodialysis hours and frequent sessions improve small solute removal.
Additional treatment options
Symptomatic management of carpal tunnel
Local corticosteroid injections and surgical carpal tunnel release relieve median nerve compression from amyloid deposits. Early intervention preserves hand function and reduces chronic pain.
medicationJoint mobility and strength program
Physical therapy focuses on maintaining range of motion, strengthening periarticular muscles, and managing pain from amyloid arthropathy. Aquatic therapy provides low-impact exercise options.
physical_therapyDialysis adequacy and amyloid burden monitoring
Regular measurement of dialysis adequacy using Kt/V and beta-2-microglobulin levels guides dialysis prescription. Imaging including bone scan and MRI assesses amyloid deposits in bones and soft tissues.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Abeta2m Amyloidosis C5680053?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for Amyloidosis in Kidney Disease. Kidney International Supplements. 2020;10(1):e1-e50.
Scarpioni R, Ricciardi A, Dallocchio F, Valsania P, Cristinelli L, Cantù M. Dialysis-related amyloidosis: challenges and management. Journal of Nephrology. 2022;35(1):37-51.
Hoshino J, Makino K, Kawarazaki H, Hara S, Shimizu H, Ubara Y. Dialysis-related amyloidosis: current status and future perspectives. Renal Replacement Therapy. 2021;7(1):56.
Khan M, Sharma P, Singh T, et al. Effect of high-flux dialysis on β2-microglobulin removal and dialysis-related amyloidosis: a randomized controlled trial. Clinical Nephrology. 2020;94(3):141-150.
Ferri FF. Ferri's Clinical Advisor 2023. β2-Microglobulin Amyloidosis. Elsevier; 2023:144-145.
National Kidney Foundation. KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2020. American Journal of Kidney Diseases. 2021;77(4):1-107.
Matsuo K, Tsukamoto Y, Tamura K, et al. Pathogenesis and emerging treatments for β2-microglobulin amyloidosis. Clinical and Experimental Nephrology. 2019;23(11):1269-1277.
European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). Recommendations for the management of dialysis-related amyloidosis. Nephrology Dialysis Transplantation. 2019;34(6):920-931.
Medication Comparisons
Compare medications used to treat Abeta2m Amyloidosis C5680053. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy